Agios Pharmaceuticals (AGIO)

$25.32 -0.42 (-1.63%)
Market Cap 1.51B
Revenue (ttm) 54.03M
Net Income (ttm) -412.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -763.98%
Debt to Equity Ratio 0.00
Volume 972,400
Avg Vol 1,042,972
Day's Range N/A - N/A
Shares Out 58.59M
Stochastic %K 4%
Beta 0.79
Analysts Strong Sell
Price Target $41.50

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
Dkll303
Dkll303 Apr. 25 at 1:02 AM
$SRPT way back , I owned this at $28….got out at $105..in 2017 ..I felt ahaead of itself then .doug came as ceo in july 2017, I was vacationing in France . He put 2M of his own money in at $44, and started his gig. Within 1 year of that July he vowed not to sell the company for less than $185. He had his chance . Since 2018 , lots of ups and downs , which I played with more successes , he now he wants out ( having never selling his Orange County home ) it was always a take out . How it plays out now, is anyone’s guess . All stated is true, for the losers sitting with TAK at $CADL and the misfits running a welfare office for themselves at $AGIO .read it and weep , you pathetic fools
2 · Reply
Dkll303
Dkll303 Apr. 24 at 8:46 PM
$AGIO SSDD at the campus of AGIOS Losers abound But wait Morgan Stanley will do a run before June 30, 2026 , so the losers options are almost green , hahahaha Get the check book ready Goff to pay Morgan for the pump
0 · Reply
stu4
stu4 Apr. 24 at 2:32 PM
$AGIO GOFF Looking to establish a NEW LOW under his pathetic reign They will be known as the Bobsey Twins Fouse and Goff We won’t mention that their EX leader Shitkien , Schenkien did the same thing in 2015 , to BIG MONEY HOLDERS from $80 to $15 …a company plagued with losers
0 · Reply
stu4
stu4 Apr. 24 at 1:31 PM
$AGIO Hahahaha …hahahah
0 · Reply
stu4
stu4 Apr. 24 at 1:27 PM
$AGIO Where are the clowns expecting a bounce from Brian Goff and his misfits ??? , Told ya, they are all rejects from other biotechs
0 · Reply
stu4
stu4 Apr. 24 at 1:25 PM
$AGIO DAH ..it has been since FOUSE showed up in 2018 , hahahah She brought her past from BUNGE here Both hit new lows under her bullshit AGIO $16.95 in 2022 Bunge $11 Tell the board something new, or shut the F up @Arcides
0 · Reply
Arcides
Arcides Apr. 23 at 9:45 PM
$AGIO price action is getting worse
0 · Reply
Dkll303
Dkll303 Apr. 22 at 10:27 AM
$AGIO I’d agree , then they brought in another bouncing hack , Krishnan, to supplement Milanova , and both have failed any sizeable increase in sales ! not one , but 2 losers in marketing
1 · Reply
Dkll303
Dkll303 Apr. 22 at 10:24 AM
$AGIO the Fouse and Goff , collection ! Not sneakers or hats, or ties , or gold coins…..just their private collection of accomplishments since arriving at AGIOS …their tale of accomplishments, matches those of Donald Trump, although not accusations of sexual assault exist yet on campus at Sidney st Cambridge, ma . I do believe , I don’t see …GREEN , for that is only displaced at the Master’s tournament, not the fcuk ups of Fouse/Goff . Quarterly , a check is written to Morgan Stanley , their brokerage facilitator, to move the stock up, for cashing in options !!! And it still can’t go Green ! LOSERS
0 · Reply
stu4
stu4 Apr. 21 at 10:51 PM
$AGIO as interesting as a hore house with no customers due to the class of hoes , got the same in management here Milanova hasn’t got a marketing plan after 4 years , but she is a crony buddy of Goff, as Fouse was a crony failure of Celgene with Schenkien. A loser group all around
0 · Reply
Latest News on AGIO
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Apr 6, 2026, 7:00 AM EDT - 19 days ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 8:45 AM EDT - 24 days ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 31, 2026, 7:00 AM EDT - 25 days ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Mar 2, 2026, 7:00 AM EST - 7 weeks ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 12, 2026, 6:30 AM EST - 2 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 26, 2026, 7:00 AM EST - 3 months ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 12, 2026, 7:00 AM EST - 3 months ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 5, 2026, 7:00 AM EST - 3 months ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 9:56 AM EST - 4 months ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:22 AM EST - 4 months ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 23, 2025, 7:45 PM EST - 4 months ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Dec 8, 2025, 7:00 AM EST - 4 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Why Is Agios Pharmaceuticals Stock Sinking Today?

Nov 19, 2025, 12:30 PM EST - 5 months ago

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:24 AM EST - 5 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 19, 2025, 7:00 AM EST - 5 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 6 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 6:30 AM EDT - 6 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:15 AM EDT - 6 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 18, 2025, 5:49 AM EDT - 7 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 7 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 10:49 AM EDT - 8 months ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 8 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 9 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 9 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 10 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 10 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 11 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 11 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 1 year ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 9, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 6:30 AM EDT - 1 year ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 5, 2025, 5:52 PM EST - 1 year ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Mar 4, 2025, 7:00 AM EST - 1 year ago

Agios to Present at Upcoming Investor Conferences

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:31 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 13, 2025, 6:30 AM EST - 1 year ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 6, 2025, 7:00 AM EST - 1 year ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Jan 8, 2025, 8:00 AM EST - 1 year ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 3, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Dkll303
Dkll303 Apr. 25 at 1:02 AM
$SRPT way back , I owned this at $28….got out at $105..in 2017 ..I felt ahaead of itself then .doug came as ceo in july 2017, I was vacationing in France . He put 2M of his own money in at $44, and started his gig. Within 1 year of that July he vowed not to sell the company for less than $185. He had his chance . Since 2018 , lots of ups and downs , which I played with more successes , he now he wants out ( having never selling his Orange County home ) it was always a take out . How it plays out now, is anyone’s guess . All stated is true, for the losers sitting with TAK at $CADL and the misfits running a welfare office for themselves at $AGIO .read it and weep , you pathetic fools
2 · Reply
Dkll303
Dkll303 Apr. 24 at 8:46 PM
$AGIO SSDD at the campus of AGIOS Losers abound But wait Morgan Stanley will do a run before June 30, 2026 , so the losers options are almost green , hahahaha Get the check book ready Goff to pay Morgan for the pump
0 · Reply
stu4
stu4 Apr. 24 at 2:32 PM
$AGIO GOFF Looking to establish a NEW LOW under his pathetic reign They will be known as the Bobsey Twins Fouse and Goff We won’t mention that their EX leader Shitkien , Schenkien did the same thing in 2015 , to BIG MONEY HOLDERS from $80 to $15 …a company plagued with losers
0 · Reply
stu4
stu4 Apr. 24 at 1:31 PM
$AGIO Hahahaha …hahahah
0 · Reply
stu4
stu4 Apr. 24 at 1:27 PM
$AGIO Where are the clowns expecting a bounce from Brian Goff and his misfits ??? , Told ya, they are all rejects from other biotechs
0 · Reply
stu4
stu4 Apr. 24 at 1:25 PM
$AGIO DAH ..it has been since FOUSE showed up in 2018 , hahahah She brought her past from BUNGE here Both hit new lows under her bullshit AGIO $16.95 in 2022 Bunge $11 Tell the board something new, or shut the F up @Arcides
0 · Reply
Arcides
Arcides Apr. 23 at 9:45 PM
$AGIO price action is getting worse
0 · Reply
Dkll303
Dkll303 Apr. 22 at 10:27 AM
$AGIO I’d agree , then they brought in another bouncing hack , Krishnan, to supplement Milanova , and both have failed any sizeable increase in sales ! not one , but 2 losers in marketing
1 · Reply
Dkll303
Dkll303 Apr. 22 at 10:24 AM
$AGIO the Fouse and Goff , collection ! Not sneakers or hats, or ties , or gold coins…..just their private collection of accomplishments since arriving at AGIOS …their tale of accomplishments, matches those of Donald Trump, although not accusations of sexual assault exist yet on campus at Sidney st Cambridge, ma . I do believe , I don’t see …GREEN , for that is only displaced at the Master’s tournament, not the fcuk ups of Fouse/Goff . Quarterly , a check is written to Morgan Stanley , their brokerage facilitator, to move the stock up, for cashing in options !!! And it still can’t go Green ! LOSERS
0 · Reply
stu4
stu4 Apr. 21 at 10:51 PM
$AGIO as interesting as a hore house with no customers due to the class of hoes , got the same in management here Milanova hasn’t got a marketing plan after 4 years , but she is a crony buddy of Goff, as Fouse was a crony failure of Celgene with Schenkien. A loser group all around
0 · Reply
stu4
stu4 Apr. 21 at 10:49 PM
$AGIO you are not so intelligent to invest in biotech misfits Not an A class scientist left here. Snowden left, tired of the Fouse lies. Goff has no science skill set, they are all public company blood suckers , sellers of options quarterly, and you invest in these clowns …better to take liquid gasoline than to spend money here ….but I warned you @Martinez2k19
1 · Reply
Martinez2k19
Martinez2k19 Apr. 21 at 10:38 PM
$AGIO awesome entry after some serious bleeding
0 · Reply
stu4
stu4 Apr. 21 at 7:17 PM
$AGIO…nothing great has come from the reign of FOUSE or GOFF …you are fooling yourself , their “ hyped “ goals are not even hit on time , they fuck up too much @chole1 Oh Danny Boy, you’d be better off farming sheep that waiting for these retards to create value
0 · Reply
XQuise
XQuise Apr. 21 at 7:14 PM
$AGIO ...seen bottom twice ($26.05), it's getting interesting 👀
0 · Reply
stu4
stu4 Apr. 21 at 6:56 PM
$AGIO how is that bounce working out ? Like a fart in church , or a hoe that that gave you the crabs !!! Hahaha . You picked the wrong ticker, this company is run by reject biotech managers , that can’t create value
1 · Reply
adiq3
adiq3 Apr. 21 at 2:35 PM
$AGIO ok here we go
0 · Reply
Omegacy2
Omegacy2 Apr. 21 at 4:34 AM
$AGIO i am in 27.01 near the close. it now 27.07. i short $BEG 57.99 second times after cash out 50 few days ago it drop 49s from short 58. it now 57.74. i play long and short. i post lesser msgs.
3 · Reply
Lanuchbox
Lanuchbox Apr. 21 at 1:56 AM
$AGIO Check out this good informative video overview https://youtu.be/JNZMakXXvRg?si=e9aKnx4rRmtgmmGV
0 · Reply
Dkll303
Dkll303 Apr. 20 at 11:06 PM
$AGIO degenerate Brian Goff… The joke of wall st ….the whole senior level is loaded with washed up biotech rejects from other companies. Nov 19 2025, wasn’t enough…..their story has lies, the lies hit again, Patriots Day in Boston . No patriots at this company, just blood suckers that couldn’t get a job in the private sector, why? They are non-performing individuals. Imagine , Fouse and Schenkien paid BMY , $48 a share in 2022 , in a buy back ..how fcuking Dumb could they be. Goff has options at $29.38, he can’t even make them green for himself after 4 fcukin years…CLOSE THE FCUKIN DOORS, YOU ARE ALL FAILURES
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 20 at 8:19 PM
$AGIO “Selloff week”? These guys are decades away from profitable use of AI.
0 · Reply
Dkll303
Dkll303 Apr. 20 at 8:12 PM
$AGIO these misfits have ruined their reputation on wall st They never have a bounce How could they they are all quarterly sellers , every quarter. Never buyers @BryanGreenwater …hopeless cause , save you money !!!
0 · Reply
Arcides
Arcides Apr. 20 at 6:49 PM
$AGIO sellers are in control on this stock, price is below vwap from that big selloff week.
1 · Reply